X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 12, 2019

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2026

Conditions

Nonsmall Cell Lung CancerBrain Metastases

Interventions

DRUG

X-396(Ensartinib) Capsule

All consented, enrolled, eligible patients receive X-396 capsules, 225mg once daily.

Trial Locations (1)

Cancer Hospital Chinese Academy Of Medical Sciences, Shenzhen Center, Shenzhen